Lotus Pharmaceutical Co., Ltd.

Lotus Pharmaceutical is the largest pharmaceutical company in Taiwan and a leading global player in the specialty generics market. Founded in 1966, the company has transformed from a local manufacturer into a multinational powerhouse with a strategic focus on high-barrier generics, particularly in oncology, CNS, and cardiovascular health. Lotus operates a hybrid business model that integrates internal R&D for complex generics with strategic licensing of innovative 505(b)(2) products and biosimilars. The company is a key pillar of the Alvogen/Aztiq network and recently significantly expanded its global footprint by acquiring Alvogen's US operations in late 2025. With manufacturing facilities in Taiwan and South Korea that are certified by the US FDA, EU EMA, and Japan PMDA, Lotus is one of the few Asian companies capable of delivering high-potency oral oncology products to highly regulated global markets.